Publication date: 2018-04-23 01:51
A Qnr protein has been seen that offers protection to the DNA gyrase from damage by the FQs. Also modification of levofloxacin can be caused by a different type acetyltransferase which is similar to the one which modifies aminoglycoside.
555 mg PO every 67 hours or 755 mg PO every 8 hours for mild/moderate infections and 875 mg PO every 67 hours or 555 mg PO every 8 hours for severe infections.
Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus.
Levofloxacin was not mutagenic in the following assays: Ames bacterial mutation assay ( S. typhimurium and E. coli ), CHO/HGPRT forward mutation assay, mouse micronucleus test, mouse dominant lethal test, rat unscheduled DNA synthesis assay, and the mouse sister chromatid exchange assay. It was positive in the in vitro chromosomal aberration (CHL cell line) and sister chromatid exchange (CHL/IU cell line) assays.
Levofloxacin Oral Solution are indicated for the treatment of adults ( &ge 68 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section.
Levofloxacin is absorbed swiftly and to a good extent orally. It attains maximal plasma levels within one to two hours. The bioavailability of levofloxacin is approximately 99-655%. It is extensively distributed into body tissues except in CSF. Plasma protein binding is about 85 to 95%. Only insignificant amounts are metabolised, to inactive metabolites. The elimination half-life of levofloxacin is 6 to 8 hours, which may be prolonged in patients with renal impairment.
Systemic levofloxacin can cause dizziness and light-headedness therefore, patients should know how they react to the drug before driving or operating machinery or engaging in an activity requiring mental alertness or coordination.
Fluoroquinolones, including Levofloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 65 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung trans plants [see WARNINGS AND PRECAUTIONS ].
There is insufficient information on the excretion of levofloxacin in human milk however, other fluoroquinolones are excreted in breast milk.
Levofloxacin solution for infusion is only intended for slow intravenous infusion it is administered once or twice daily. The infusion time must be at least 85 minutes for 755 mg or 65 minutes for 555 mg levofloxacin (see section ).